15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Local hormone therapy for genitourinary syndrome of menopause in breast cancer patients: is it safe?

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The genitourinary syndrome of menopause (GSM) is a frequent complaint among breast cancer (BC) survivors that lead to an important affection of their quality of life (QoL). Lifestyle measures such as smoking cessation or regular sexual activity are usually insufficient to significantly improve GMS and although therapies such as lubricants and polycarbophil moisturized gels are considered first-line therapies to alleviate symptoms of vulvovaginal atrophy, these non-hormonal options are not able to reverse atrophy once it occurs. Instead, this complaint is corrected by local estrogens. The estrogen vaginal treatment usually used to treat GSM, is an issue of concern in this group due to the possible negative effect over the BC outcomes. On the other hand, the worsening of QoL in these patients due to symptoms related to GSM can lead to discontinuation of hormone adjuvant therapies and therefore must be addressed properly. The goal of this review is to contribute to health care professionals to make an informed decision to care for their BC patients.

          Related collections

          Author and article information

          Journal
          Gynecol. Endocrinol.
          Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
          Informa UK Limited
          1473-0766
          0951-3590
          Jun 2017
          : 33
          : 6
          Affiliations
          [1 ] a Department of Obstetrics & Gynecology and Reproductive Biology, Faculty of Medicine , Universidad de los Andes , Santiago , Chile and.
          [2 ] b Clinic Institute of Gynecology, Obstetrics and Neonatology, Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona , Barcelona , Spain.
          Article
          10.1080/09513590.2017.1290076
          28277141
          3fbf3346-2cb3-4eb4-906d-ab334d9b07de
          History

          Breast cancer,genitourinary syndrome,hormonal therapy,local estrogen therapy,ospemifene,promestriene,vulvovaginal atrophy

          Comments

          Comment on this article